blinatumomab,inotuzumab
astellas pharmaceuticals,amgen,ucb,pfizer
['leusm', 'blinatumomab', 'inotuzumab']
congress #eha22 | presented results from a phase ii study of mini-hyper cvd + inotuzumab ozogamicin +/- blinatumomab in pts 60 years with nd ph-ve b-all. n=80. 99% responded, 89% cr. 80% pts were mrd-ve after 1 cycle &amp; 94% overall #allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm